Safety profile of meglumine antimoniate intralesional infiltration for cutaneous leishmaniasis

References

• Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual de vigilância da leishmaniose tegumentar [recurso eletrônico]/Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis.–Brasília : Ministério da Saúde; 2017. p. 189. il. Available from: <http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_leishmaniose_tegumentar.pdf>
   Google Scholar
• Datasus.saude.gov.br [homepage on the Internet]. Departamento de informática do SUS. [updated 2017; cited 2019 20]. Available from: http://datasus.saude.gov.br/
   Google Scholar
• Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One. 2017;12(9): 0184777–99.
   Web of Science ®Google Scholar
• Silva RE, Junior AT, Senna MC, et al. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre. Memórias Inst Oswaldo Cruz. 2016;111(8):512–516.
   PubMed Web of Science ®Google Scholar
• Ramalho DB, Silva RE, Senna MCR, et al. Meglumine antimoniate intralesional infiltration for localized cutaneous leishmaniasis: a single arm, open label, phase II clinical trial. Memórias Inst Oswaldo Cruz. 2018;113(9):1–8.
   PubMed Web of Science ®Google Scholar
• Silva RE, Carvalho JP, Ramalho DB, et al. Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment. Memórias Inst Oswaldo Cruz. 2018;113(2):71–79.
   PubMed Web of Science ®Google Scholar
• U.S. Department of health and human services, national institutes of health, national institute of allergy and infectious diseases, division of AIDS. Division of AIDS (DAIDS). Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.. 2017 July. [cited 2019 20]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
   Google Scholar
• Anvisa. Manual para notificação de eventos adversos e monitoramento de segurança em ensaios clínicos. Brazil: Anvisa; 2016. p. 18.
   Google Scholar
• WHO/UMC -World Health Organization/The Uppsala Monitor-ing Centre. WHO collaborating centre for international drug monitoring. WHO-UMC causality assessment. [cited 2019 25]. Available from: http://www.who-umc.org/Graphics/26649.pdf
   Google Scholar
• Blum J, Lockwood DNJ, Visser L, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health. 2012;4(3):153–163.
   PubMed Web of Science ®Google Scholar
• Monge-Maillo B, López-Vélez R. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis. Drugs. 2013;73(17):1889–1920.
   PubMed Web of Science ®Google Scholar
• Esfandiarpour I, Farajzadeh S, Rahnama Z, et al. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2012;51(10):1221–1225.
   PubMed Web of Science ®Google Scholar
• Oliveira-Neto MP, Schubach AO, Mattos M, et al. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania (V.) braziliensis transmission. Int J Dermatol. 1997c;36(6):463–468.
   PubMed Web of Science ®Google Scholar
• Aste N, Pau M, Ferreli C, et al. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate. Br J Dermatol. 1998;138(2):370–371.
   PubMed Web of Science ®Google Scholar
• Soto J, Rojas E, Guzman M, et al. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clinl Infect Dis. 2013;56(9):1255–1260.
   PubMed Web of Science ®Google Scholar
• Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs. 1998;56(6):1009–1018.
   PubMed Web of Science ®Google Scholar
• Yesilova Y, Surucu HA, Ardic N, et al. Meglumine antimoniate is more effective than sodium stibogluconate in the treatment of cutaneous leishmaniasis. J Dermatological Treat. 2015;27(1):83–87.
   PubMed Web of Science ®Google Scholar
• Vasconcellos ECF, Pimentel MIF, Schubach AO, et al. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg. 2012;87(2):257–260.
   PubMed Web of Science ®Google Scholar
• Gadelha AR, Oliveira WC, Assunção IJ, et al. Tratamento da leishmaniose tegumentar americana com injeções intralesionais de N-metil-glucamina. An Bras Dermatol. 1990;4(65):201–203.
   Google Scholar
• Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clinl Infect Dis. 2016;63(12):202–264.
   PubMed Web of Science ®Google Scholar
• Freitas PFS, Borges RR, Leal BHS, et al. Avaliação do eletrocardiograma de pacientes com leishmaniose tegumentar americana tratados com antimonial pentavalente (glucantime®). Rev Patologia Trop. 2015;43(4):405–411.
   Google Scholar
• Neves DBJ, Caldas ED, Sampaio RNR. Antimony in plasma and skin of patients with cutaneous leishmaniasis - relationship with side effects after treatment with meglumine antimoniate. Trop Med Int Health. 2009;14(12):1515–1522.
   PubMed Web of Science ®Google Scholar
• İlgenli TF, Tokatli A, Akipinar O, et al. The effects of cigarette smoking on the TP-e interval, TP-e/QT ratio and TP-e/QTc ratio. Adv Clin Exp Med. 2015;24(6):973–978.
   PubMed Web of Science ®Google Scholar
• Thomakos P, Liatis S, Kalopita S, et al. Cigarette smoking is associated with prolongation of the QTc interval duration in patients with type 2 diabetes mellitus. Int J Endocrinol. 2013;1–7.
   Google Scholar
• Aguiar MG, Gonçalves JE, Souza MA, et al. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate. Trop Med Int Health. 2018;23(10):1110–1117.
   PubMed Web of Science ®Google Scholar
• Cruz A, Reiney PM, Herwaldt BL, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis. 2017;195(4):602–608.
   Web of Science ®Google Scholar
• Zaghloul IY, Radwan MA, Al Jaser MH, et al. Pharmacokinetics of antimony in cutaneous leishmaniasis patients treated with sodium stibogluconate. J Clin Pharmacol. 2010;50(11):1230–1237.
   PubMed Web of Science ®Google Scholar